Suppose your kidneys are the party rogue, quietly disarming traps while your heart paladin barrels down the corridor yelling, "I have excellent armor, this is fine." Zoccali and colleagues' review makes that scenario slightly less absurd: in early chronic kidney disease, the heart may already be taking damage before anyone sees the big red "heart failure" dragon on the map.

The paper, published in the European Heart Journal, argues that many people with early CKD may already be in "pre-heart failure" territory - Stage B heart failure, in campaign terms - even when they have no obvious symptoms. No dramatic chest-clutching. No swelling montage. Just the ominous dungeon music getting louder while the character sheet still says "apparently okay" (Zoccali et al., 2026).

The Kidney-Heart Party Is Sharing Hit Points

Chronic kidney disease, or CKD, means the kidneys have had abnormal structure or function for at least three months. Clinicians usually track it with eGFR, a rough estimate of filtration power, and albuminuria, which means protein is leaking into urine like a tavern roof in a thunderstorm. CKD affects roughly 10%-15% of adults worldwide, so this is not a rare side quest.

The twist is that early CKD - stages G1 to G3, especially with albuminuria - does not stay politely inside the kidney chapter. It raises the risk of left ventricular hypertrophy, concentric remodeling, diastolic dysfunction, arrhythmias, myocardial fibrosis, and HFpEF: heart failure with preserved ejection fraction.

HFpEF is the annoying boss who looks healthy because the heart still squeezes out a normal percentage of blood, but the ventricle has become stiff and cranky. It can pump, sure. It just fills badly. Like a suitcase packed by someone who refuses to fold shirts.

Stage B: The Boss Fight Before the Boss Fight

Modern heart failure staging includes a pre-HF stage: no symptoms yet, but the structure, function, or biomarkers suggest trouble is brewing. Zoccali's group says early CKD often fits this pattern. The heart is not necessarily failing in the cinematic sense. It is taking stealth damage.

This matters because symptoms are terrible narrators. Fatigue? Could be CKD, anemia, sleep, aging, work stress, or Tuesday. Shortness of breath? Same problem. Biomarkers such as natriuretic peptides can help, but kidney impairment muddies the signal because reduced renal clearance can keep levels elevated. The dice are loaded, and the dungeon master is smiling in a way nobody likes.

So the review points to imaging as the higher-perception character in the party. Echocardiography can detect left ventricular hypertrophy, diastolic dysfunction, and strain abnormalities. Speckle-tracking echo adds extra detail. Cardiac MRI can show tissue changes and fibrosis. But there is a catch: routine imaging screening for every asymptomatic early CKD patient is not currently recommended. The scan spell is powerful, but expensive, time-consuming, and not yet proven as a universal strategy.

The Healing Items Are Getting Better

The treatment section reads like a medicine cabinet built by a careful wizard. Control blood pressure. Reduce albuminuria. Manage diabetes, obesity, salt, congestion, and cardiovascular risk. Use renin-angiotensin system blockers when appropriate. Use diuretics when volume overload appears.

Then come the newer items: SGLT2 inhibitors, which started life as diabetes drugs and somehow became cardiorenal multitools. This is the kind of plot development that makes pharmacology feel like a long-running fantasy series with too many spin-offs. Recent guidelines and trials support SGLT2 inhibitors for kidney and heart protection across multiple patient groups, including CKD and heart failure populations (KDIGO, 2024; Vaduganathan et al., 2022).

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, also enters the party. In FINEARTS-HF, finerenone reduced worsening heart failure events in patients with mildly reduced or preserved ejection fraction, though clinicians still need to watch potassium like it is a cursed amulet (Solomon et al., 2024).

GLP-1 receptor agonists may help selected patients too, especially where obesity and HFpEF overlap. Semaglutide improved symptoms and exercise function in people with obesity-related HFpEF, which suggests that sometimes the best way to fight the heart dragon is to deal with the metabolic swamp it lives in (Kosiborod et al., 2023).

Where AI Joins the Campaign

The authors also flag multiomics and artificial intelligence as future tools for sorting this messy condition into more meaningful subtypes. That is the right kind of AI job: not "replace the cleric," but "find patterns in 40,000 variables without needing six coffees and a spreadsheet sacrifice." AI models could eventually combine labs, imaging, genetics, proteins, and clinical history to predict which CKD patients are quietly marching toward HFpEF.

But that future quest still needs validation. Medical AI loves to look brilliant in one dataset and then trip over a hospital hallway rug somewhere else. The next boss battles are cost-effective screening, better biomarker interpretation in CKD, and trials showing that earlier detection actually changes outcomes.

The Takeaway Scroll

Zoccali and colleagues are not saying every early CKD patient needs a cardiac MRI tomorrow morning. They are saying the kidney-heart link starts earlier than many people assume, and the "no symptoms" phase may hide structural cardiac changes worth taking seriously.

For clinicians and researchers, the campaign objective is clear: identify the high-risk players earlier, treat aggressively but sensibly, and prove which screening strategies earn their spell slots. For the rest of us, the lesson is simpler: kidneys are not side characters. When they start sending warning signals, the heart may already be rolling saving throws.

References

1. Zoccali C, De Caterina R, Tuttle KR, Burnier M, Massy ZA, Mallamaci F, Ferro CJ, Zannad F. Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment. European Heart Journal. 2026. DOI: 10.1093/eurheartj/ehag220. PMID: 41914187.

2. Kidney Disease: Improving Global Outcomes. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Guideline PDF.

3. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. Journal of the American College of Cardiology. 2023;81(18):1810-1834. DOI: 10.1016/j.jacc.2023.01.049.

4. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. 2024;391:1475-1485. DOI: 10.1056/NEJMoa2407107.

5. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023;389:1069-1084. DOI: 10.1056/NEJMoa2306963.

Disclaimer: This blog post is a simplified summary of published research for educational purposes. The accompanying illustration is artistic and does not depict actual model architectures, data, or experimental results. Always refer to the original paper for technical details.